Results 111 to 120 of about 25,328 (173)

Cost-effectiveness of tremelimumab plus durvalumab versus sorafenib for unresectable hepatocellular carcinoma in China: an economic evaluation based on five-year overall survival data from the HIMALAYA trial. [PDF]

Front Public Health
Feng R, Liang P, Wang Y, Li D, Jia H, Zheng Y, Huo L, Lv Q.   +7 more
europepmc   +1 more source

IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers. [PDF]

Cancer
Manning WB, Youssef AM, Yeku OO.
europepmc   +1 more source

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer. [PDF]

Clin Cancer Res
Schmid P, Ma CX, Park YH, Lord S, Armstrong A, Im SA, Chen SC, Fernandes R, Jassem J, Wysocki PJ, Lu YS, Wang HC, Chung WP, Rao-Melacini P, Heider K, Stewart R, Vuković P, Jung KH.   +17 more
europepmc   +1 more source

Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study. [PDF]

BMC Cancer
Aoki S, Ariyasu R, Kamima T, Sato Y, Tokumasu K, Anno W, Ogura Y, Kaneko M, Mun M, Ninomiya H, Nishio M, Yoshioka Y.   +11 more
europepmc   +1 more source

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

JAMA Oncol
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW.   +9 more
europepmc   +1 more source

Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report. [PDF]

Oncologist
Hang Y, Bai L, Hsu H, Chen Y, Wang F, Xu W, Zhen X, Wang Z, Li Y, Qian J.   +9 more
europepmc   +1 more source

Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial. [PDF]

Oncol Ther
Sun Y, Zhong J, Sun H, Parr G, Lukacs E, Slade D, Zhou Y, Ren X, Kirk D, Kmieciak A, Yao T, Wang J.   +11 more
europepmc   +1 more source

Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma. [PDF]

Liver Cancer
Rimassa L, Dayyani F, Kelley RK, Sangro B, Chan SL, Nakamura H, Clark L, Xynos I, Abou-Alfa GK.   +8 more
europepmc   +1 more source

Real-World Efficacy and Safety of Gemcitabine, Cisplatin, Plus Immune Checkpoint Inhibitors in Biliary Tract Cancer: A Retrospective Analysis. [PDF]

Cancers (Basel)
Kitahara M, Saito K, Oki Y, Kuniyoshi N, Nomura S, Fujisawa M, Kogure H.   +6 more
europepmc   +1 more source